Pumosetrag

DB12402InvestigationalSmall molecule

Pumosetrag has been used in trials studying Gastroesophageal Reflux Disease.

Mechanism: Pharmacologically active on 5-hydroxytryptamine receptor 3
Curator reviewed
Formula / weight: C₁₅H₁₇N₃O₂S · 303.38 g/mol (avg)

Resolves to

Compound

Structure

InChIKeyAFUWQWYPPZFWCO-LBPRGKRZSA-NSMILESO=C(N[C@H]1CN2CCC1CC2)C1=CNC2=C(SC=C2)C1=O

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Pumosetrag, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.